In vitro reports have shown really small opportunity for semaglutide to inhibit or induce CYP enzymes, and to inhibit drug transporters. Some reports propose that although the incidence of gastrointestinal adverse situations is comparable to that of GLP-1 receptor agonists, the twin system of action may give pros regarding cardiovascular Positiv